Literature DB >> 28319737

Relationship between C9orf72 repeat size and clinical phenotype.

Sara Van Mossevelde1, Julie van der Zee2, Marc Cruts2, Christine Van Broeckhoven3.   

Abstract

Patient carriers of a C9orf72 repeat expansion exhibit remarkable heterogeneous clinical and pathological characteristics suggesting the presence of modifying factors. In accordance with other repeat expansion diseases, repeat length is the prime candidate as a genetic modifier. Observations of earlier onset ages in younger generations of large families suggested a mechanism of disease anticipation. Yet, studies of repeat size and onset age have led to conflicting results. Also, the correlation between repeat size and diagnosis is poorly understood. We review what has been published regarding C9orf72 repeat size as modifier for phenotypic characteristics. Conclusive evidence is lacking, partly due to the difficulties in accurately defining the exact repeat size and the presence of repeat variability due to somatic mosaicism.
Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28319737     DOI: 10.1016/j.gde.2017.02.008

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN: 0959-437X            Impact factor:   5.578


  43 in total

1.  Validation of a Long-Read PCR Assay for Sensitive Detection and Sizing of C9orf72 Hexanucleotide Repeat Expansions.

Authors:  EunRan Suh; Kaitlyn Grando; Vivianna M Van Deerlin
Journal:  J Mol Diagn       Date:  2018-08-20       Impact factor: 5.568

Review 2.  Links Between the C9orf72 Repeat Expansion and Psychiatric Symptoms.

Authors:  Hannah E Silverman; Jill S Goldman; Edward D Huey
Journal:  Curr Neurol Neurosci Rep       Date:  2019-11-26       Impact factor: 5.081

3.  C9orf72 Intermediate Alleles in Patients with Amyotrophic Lateral Sclerosis, Systemic Lupus Erythematosus, and Rheumatoid Arthritis.

Authors:  Micaela Fredi; Ilaria Cavazzana; Giorgio Biasiotto; Massimiliano Filosto; Alessandro Padovani; Eugenio Monti; Angela Tincani; Franco Franceschini; Isabella Zanella
Journal:  Neuromolecular Med       Date:  2019-03-11       Impact factor: 3.843

4.  Survival and Prognostic Factors in C9orf72 Repeat Expansion Carriers: A Systematic Review and Meta-analysis.

Authors:  Stella A Glasmacher; Charis Wong; Iona E Pearson; Suvankar Pal
Journal:  JAMA Neurol       Date:  2020-03-01       Impact factor: 18.302

5.  Phase Separation of Toxic Dipeptide Repeat Proteins Related to C9orf72 ALS/FTD.

Authors:  Hamidreza Jafarinia; Erik van der Giessen; Patrick R Onck
Journal:  Biophys J       Date:  2020-07-16       Impact factor: 4.033

Review 6.  Fly for ALS: Drosophila modeling on the route to amyotrophic lateral sclerosis modifiers.

Authors:  Francesco Liguori; Susanna Amadio; Cinzia Volonté
Journal:  Cell Mol Life Sci       Date:  2021-07-28       Impact factor: 9.261

Review 7.  Antisense Oligonucleotide Therapies for Neurodegenerative Diseases.

Authors:  C Frank Bennett; Adrian R Krainer; Don W Cleveland
Journal:  Annu Rev Neurosci       Date:  2019-07-08       Impact factor: 12.449

Review 8.  C9orf72 and its Relevance in Parkinsonism and Movement Disorders: A Comprehensive Review of the Literature.

Authors:  Thomas Bourinaris; Henry Houlden
Journal:  Mov Disord Clin Pract       Date:  2018-11-08

9.  ALS/FTD-Associated C9ORF72 Repeat RNA Promotes Phase Transitions In Vitro and in Cells.

Authors:  Marta M Fay; Paul J Anderson; Pavel Ivanov
Journal:  Cell Rep       Date:  2017-12-19       Impact factor: 9.423

Review 10.  A Systematic and Comprehensive Review on Disease-Causing Genes in Amyotrophic Lateral Sclerosis.

Authors:  E Srinivasan; R Rajasekaran
Journal:  J Mol Neurosci       Date:  2020-05-15       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.